Cerevance reported Phase 3 progress for solengepras, an oral therapy for Parkinson’s disease aimed at reducing patients’ daily “off” time. In the trial, the company said solengepras cut off-time alongside other symptoms, and it plans to engage regulators about a potential approval. Cerevance positioned solengepras as distinct from dopamine-targeting therapies by inhibiting a protein involved in coordination and motor function. In trial design, 341 participants were randomized to placebo or two solengepras doses, with the higher dose meeting the main endpoint at 12 weeks. The company said safety results were generally tolerable, with most adverse events in the higher-dose group described as mild to moderate, including headache, urinary tract infection, insomnia, and nausea.